MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan from the BioInnovation Institute Foundation (BII) in Copenhagen, Denmark, to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previously incurable muscle diseases using its innovative muscle stem cell technology. The MyoPax project has been supported by the SPARK Program since 2016.
The BII supports ventures that are strategically aligned with the incubator’s focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
More information about MyoPax.
More information about BII BioInnovation Institute Foundation.
For more information, please see BIH press release.